→  Anap­tys­Bio CSO Matthew Moyle has abrupt­ly re­signed and left the com­pa­ny. An SEC fil­ing notes he got nine months salary as sev­er­ance.

→ An­drea van El­sas, the chief sci­en­tif­ic of­fi­cer of Aduro Biotech Eu­rope, will be ap­point­ed chief sci­en­tif­ic of­fi­cer of the moth­er com­pa­ny Aduro Biotech in Berkley, CA.

→ Mon­cef Slaoui, the for­mer R&D and vac­cines chief at Glax­o­SmithK­line, is join­ing the board at the mR­NA com­pa­ny Mod­er­na. Slaoui is an en­thu­si­as­tic cham­pi­on of pi­o­neer­ing drug R&D. And he says he’s look­ing “for­ward to work­ing with the team to nav­i­gate this un­chart­ed ter­ri­to­ry, and sup­port the strate­gic plan­ning al­ready un­der­way as Mod­er­na works to de­liv­er mR­NA med­i­cines and vac­cines to ad­dress se­ri­ous un­met med­ical needs in the U.S. and glob­al­ly.”

→ Af­ter a year of dis­con­tent, there’s been a change at the top of France’s Na­tion­al Re­search Agency as Michael Mat­losz steps down.

→ Mer­ri­mack Phar­ma­ceu­ti­cals has ex­pand­ed its ex­ec­u­tive man­age­ment team with the ap­point­ment of Thomas E. Need­ham to the po­si­tion of chief busi­ness of­fi­cer.

→ Abeona Ther­a­peu­tics an­nounced that Juan Ruiz has joined the com­pa­ny as chief med­ical of­fi­cer.

→ PTC Ther­a­peu­tics has pro­mot­ed Joseph McIn­tosh to se­nior vice pres­i­dent and head of clin­i­cal de­vel­op­ment. McIn­tosh will be re­spon­si­ble for all as­pects of Clin­i­cal De­vel­op­ment across PTC’s port­fo­lio.

→ Ox­ford Im­munotec Glob­al an­nounced the ap­point­ment of Richard Wen­strup as chief med­ical of­fi­cer.

The German life science group Sartorius will be picking up French contract manufacturer Polyplus for the price of €2.4 billion, or $2.6 billion.

On Friday, Sartorius announced the acquisition through its French subgroup, Sartorius Stedim Biotech, which will be acquiring Polyplus from private investors ARCHIMED and WP GG Holdings IV. Polyplus has 270 employees and produces materials and components that go into making viral vectors that are used in cell and gene therapies. This includes DNA/RNA reagents as well as plasmid DNA. Polyplus has locations in France, Belgium, China and the US.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended nine drugs for approval this week while also giving thumbs up for six expanded indications, including Novo Nordisk’s approved obesity medication Wegovy for younger people. Wegovy is already approved as an obesity treatment in the EU for adults, and the new indication would allow prescriptions for adolescents aged 12 and older.

RNA biotech GreenLight Biosciences has been handed an offer for potential acquisition.

GreenLight said in a release that it has received a non-binding “indication of interest” from Fall Line Endurance Fund to acquire GreenLight’s capital stock for $0.60 per share in cash. The release said any potential agreement between the two parties would depend on certain conditions.

Through a special committee, the biotech will evaluate the offer but added there’s no certainty a deal will go forward. GreenLight will also not make any more announcements until a deal comes through or “otherwise determines” a statement is necessary.

A public T cell biotech’s chief executive has decided to leave the company.

TScan Therapeutics said Friday morning that CEO David Southwell stepped down earlier this week, leaving both his chief executive and board member roles. Filling in is Gavin MacBeath, the company’s CSO and COO. He became the acting CEO on Tuesday, and will continue to remain CSO and COO, TScan’s announcement read.